弥漫浸润性视网膜母细胞瘤:一项多中心国际数据共享研究
这项国际多中心登记回顾性病例系列分析了2001年1月至2013年12月的132眼弥漫浸润性视网膜母细胞瘤(DIR),占视网膜母细胞瘤的4.6%。DIR多表现为继发性青光眼、前节受累或眼内出血,初诊以眼球摘除为主;cT3期DIR的5年生存率82%低于非DIR cT3期的94%,转移死亡风险HR为3.3,高危病理特征更常见。
要点
- DIR占视网膜母细胞瘤的4.6%,诊断中位年龄24个月,无双眼病例。
- cT3期DIR的5年生存率82%,低于非DIR cT3期的94%(p<0.001)。
- DIR cT3期转移死亡风险高于非DIR cT3期(HR 3.3,95%CI 1.8-5.9,p<0.001)。
核心结论
- 约每20例视网膜母细胞瘤患者中有1例为DIR,常表现为青光眼、前节受累或眼内出血;DIR较非DIR cT3期更致命,眼球摘除可发现高危病理。
研究设计与样本
- 国际多中心登记回顾性病例系列,分析2001年1月至2013年12月的汇总数据,纳入132例患者的132眼DIR。
主要发现
- 2854眼中132眼(4.6%;95%CI 3.9-5.5)为DIR,诊断中位年龄24个月(IQR 15-33),无双眼病例。
- 美国癌症联合委员会分期显示cT2占4.5%、cT3占95.5%,无cT1或cT4病例。
- DIR相关临床特征包括继发性青光眼67%、视网膜脱离38%、弥漫玻璃体种植37%、前节受累24%、玻璃体出血50%和前房积血6%。
- 81%以初次眼球摘除为主要治疗,19%初始接受全身化疗,其中6%后续需眼球摘除。
- cT3期DIR的5年Kaplan-Meier生存率为82%(95%CI 78-86),低于非DIR cT3期的94%(95%CI 93-95)(p<0.001)。
关键数值与推荐
- DIR占视网膜母细胞瘤的4.6%(95%CI 3.9-5.5)。
- cT3期DIR的5年生存率为82%(95%CI 78-86)。
- DIR cT3期较非DIR cT3期转移死亡HR为3.3(95%CI 1.8-5.9;p<0.001)。
- 高危病理特征DIR 41% vs 非DIR 28%(p=0.004)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To determine the unique clinical characteristics and treatment outcomes of diffuse infiltrating retinoblastoma (DIR). METHODS: This international, multicentre, registry-based retrospective case series analysed pooled data from January 2001 to December 2013, including 132 eyes from 132 patients with DIR. RESULTS: Among 2854 eyes with retinoblastoma, 132 (4.6%; 95% CI, 3.9 to 5.5) had DIR. The median age at diagnosis for DIR patients was 24 months (IQR, 15-33), with no bilateral cases of DIR. The American Joint Committee on Cancer staging showed 4.5% cT2 and 95.5% cT3 categories, with no cT1 or cT4 cases. Clinical features associated with DIR included secondary glaucoma (67%), retinal detachment (38%), diffuse vitreous seeds (37%), anterior segment involvement (24%), vitreous haemorrhage (50%) and hyphema (6%). Primary enucleation was the predominant treatment (81%), while 19% initially received systemic chemotherapy, with 6% requiring subsequent enucleation. The 5-year Kaplan-Meier survival rate for cT3 DIR was 82% (95% CI, 78 to 86), significantly lower than the 94% (95% CI, 93 to 95) for cT3 non-DIR cases (p<0.001). Cox proportional hazards regression returned a higher risk of metastatic death for DIR cT3 compared with non-DIR cT3 (HR, 3.3; 95% CI, 1.8 to 5.9; p<0.001). High-risk pathological features were more frequent in DIR (41% vs 28%, p=0.004). There was no association between DIR and local treatment failure. CONCLUSIONS: Approximately 1 in 20 patients with retinoblastoma had DIR, which often presented with glaucoma, anterior segment involvement or intraocular bleeding. DIR was more lethal than non-DIR cT3, with enucleation revealing high-risk pathology.
引用
- Tomar AS, Finger PT, Gallie B, et al. Diffuse infiltrating retinoblastoma: a multicentre, international, data-sharing study. Br J Ophthalmol. 2025. PMID: 40738737. doi:10.1136/bjo-2024-326778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。